About Monoacylglycerol lipase ABHD6
Monoacylglycerol lipase ABHD6 (ABHD6) is a protein
from Homo sapiens identified by UniProt accession
Q9BV23, 337 residues long.
MolForge cross-references it against 0 known binders and
113 disease associations.
Target properties
| Protein name | Monoacylglycerol lipase ABHD6 |
|---|
| UniProt accession | Q9BV23 |
|---|
| Gene | ABHD6 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 337 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (2)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (113)
Diseases linked to this target (Open Targets).
- multiple sclerosis · score 0.36
- Alzheimer disease · score 0.36
- lysosomal storage disease · score 0.36
- Parkinson disease · score 0.36
- neurodegenerative disease · score 0.36
- breast adenocarcinoma · score 0.25
- ovarian cancer · score 0.09
- platelet count · score 0.09
- mean platelet volume · score 0.09
- platelet crit · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9BV23-F1 | alphafold | PREDICTED | 90.80 | — |
Amino-acid sequence (337 residues)
MDLDVVNMFV IAGGTLAIPI LAFVASFLLW PSALIRIYYW YWRRTLGMQV RYVHHEDYQF CYSFRGRPGH KPSILMLHGF SAHKDMWLSV VKFLPKNLHL VCVDMPGHEG TTRSSLDDLS IDGQVKRIHQ FVECLKLNKK PFHLVGTSMG GQVAGVYAAY YPSDVSSLCL VCPAGLQYST DNQFVQRLKE LQGSAAVEKI PLIPSTPEEM SEMLQLCSYV RFKVPQQILQ GLVDVRIPHN NFYRKLFLEI VSEKSRYSLH QNMDKIKVPT QIIWGKQDQV LDVSGADMLA KSIANCQVEL LENCGHSVVM ERPRKTAKLI IDFLASVHNT DNNKKLD
Explore Monoacylglycerol lipase ABHD6 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets